Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid?
The post Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In appeared first on MedCity News.
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Pancreatic cancer is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to the American Cancer Society,
